Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Collaboration supports multiple discovery efforts, including vaccines
Lifts full-year outlook as obesity drug boom accelerates
Subscribe To Our Newsletter & Stay Updated